California-based DNA sequencing firms Illumina and Pacific Biosciences have called off their proposed $1.2 billion merger, after deciding that the transaction would be unlikely to make it p
Epizyme’s sarcoma drug tazemetostat is set to go before an influential FDA advisory committee today, following a mixed review from the agency’s own staffers.
